artelo
biosciences
participate
two
keynote
panels
annual
international
cannabinoid
derived
pharmaceutical
summit
la
jolla
globe
newswire
artelo
biosciences
nasdaq
artl
clinical
stage
biopharmaceutical
company
developing
therapeutics
modulate
endocannabinoid
system
today
announced
gregory
gorgas
chief
executive
officer
andy
yates
phd
interim
chief
scientific
officer
participate
separate
keynote
panels
rd
annual
international
cannabinoid
derived
pharmaceuticals
summit
held
virtually
september
workshop
entitled
dealing
intellectual
property
ip
market
exclusivity
september
eastern
time
feature
gorgas
sharing
insights
regarding
ip
strategies
applicable
drug
development
alternatives
ip
protection
securing
market
exclusivity
hierarchy
strength
protection
offered
various
ip
methods
presentation
entitled
clinical
trial
design
endpoints
regulatory
strategies
september
eastern
time
yates
discussing
artelo
program
high
potency
gpcr
agonist
anorexia
associated
cancer
well
importance
consultation
regulatory
authorities
progression
clinical
development
annual
cannabinoid
derived
pharmaceutical
cdp
summit
pioneering
research
development
pharmaceuticals
containing
cannabinoid
apis
year
agenda
takes
aims
overcome
exciting
new
challenges
discuss
ongoing
issues
yet
addressed
set
tone
direction
next
months
development
providing
platform
discussion
issues
present
cdp
development
bench
bedside
meeting
comprehensive
assembly
cannabinoid
pharmaceutical
specialists
targeting
issues
important
bringing
next
generation
cdps
market
information
available
https
twitter
artelo
biosciences
artelo
biosciences
san
biopharmaceutical
company
dedicated
development
commercialization
proprietary
therapeutics
targeting
endocannabinoid
system
related
pathways
artelo
rapidly
advancing
portfolio
broadly
applicable
product
candidates
designed
address
significant
unmet
needs
multiple
diseases
conditions
including
anorexia
cancer
pain
inflammation
led
proven
biopharmaceutical
executives
collaborating
highly
respected
researchers
technology
experts
company
applies
leading
edge
scientific
regulatory
commercial
discipline
develop
therapies
information
available
twitter
artelobio
